Fargo, N.D., based company increasing capacity to better serve
rapidly growing biotech industry

Aldevron officially broke ground on its 14-acre campus expansion at its global headquarters in Fargo, North Dakota, August 19. Three buildings are planned, with construction of its next GMP manufacturing facility starting first.

Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018.